77.5 B+

DSIP

Also known as: Delta sleep-inducing peptide

Strong Clinical Evidence Research Chemical
Research Evidence 90.0/100
Safety Profile 65.0/100

68 Clinical Trials

Unknown: 6 PHASE4: 14 PHASE3: 10 PHASE2, PHASE3: 1 PHASE2: 11 PHASE1: 3 NA: 23

Showing 5 of 68 trials.

19 Research Papers

Showing 5 of 19 papers by citation count.

FDA Data

Not FDA-Approved

DSIP has not been evaluated by the FDA for safety or efficacy. It is not approved for human therapeutic use in the United States.

Frequently Asked Questions

Is DSIP FDA approved?
No, DSIP has not been approved by the FDA for human therapeutic use. It is sold as a research chemical.
How many clinical trials has DSIP been studied in?
DSIP has been studied in 68 registered clinical trials. CheckPeptides tracks phase, status, and sponsor data for each trial.
What is the trust score for DSIP?
DSIP has a CheckPeptides trust score of 77.5/100 (grade: B+). This score is based on clinical trial volume, research paper quality, FDA data, and evidence classification.
Last verified: April 8, 2026

Quick Facts

Classification
Neuropeptide
Molecular Weight
848.8 Da
Regulatory Status
N/A

Score Breakdown

Research Evidence 90.0/100
Safety Profile 65.0/100

Evidence Summary

Clinical Trials
68
Research Papers
19
Trust Score
77.5/100
Grade
B+

Compare Peptides

See how DSIP stacks up against similar peptides.

View Comparisons
← Browse all peptides